PE Fund Investments
API maker Natural BioGenex raises Rs.18.61 Cr from Somerset Indus Capital
BSE Announcement Indian Pharma Post
Healthcare-focused private equity fund Somerset Indus Capital Partners has invested INR 18.61 crore in Natural BioGenex Pvt Ltd (NBPL), a Bengaluru-based unlisted subsidiary of publicly listed Natural Capsules Ltd (NCL) at a pre-money valuation of INR 250 crore. Phillip Capital India facilitated the investment. The total investment is envisaged to be INR 75 crore. NBPL is constructing a greenfield facility in Tumkur, near Bengaluru to manufacture active pharmaceutical ingredients (APIs), including Betamethasone, Dexamethasone, and Prednisolone, along with their intermediates and derivatives.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
